MetLife Investment Management’s Meridian Bioscience Inc VIVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-23,227
| Closed | -$771K | – | 2856 |
|
|
2022
Q4 | $771K | Hold |
23,227
| – | – | 0.01% | 1356 |
|
|
2022
Q3 | $732K | Hold |
23,227
| – | – | 0.01% | 1368 |
|
|
2022
Q2 | $707K | Hold |
23,227
| – | – | 0.01% | 1423 |
|
|
2022
Q1 | $603K | Buy |
23,227
+8,516
| +58% | +$203K | ﹤0.01% | 1659 |
|
|
2021
Q4 | $300K | Hold |
14,711
| – | – | ﹤0.01% | 1812 |
|
|
2021
Q3 | $283K | Sell |
14,711
-4,215
| -22% | -$84K | ﹤0.01% | 1857 |
|
|
2021
Q2 | $420K | Hold |
18,926
| – | – | ﹤0.01% | 1673 |
|
|
2021
Q1 | $497K | Hold |
18,926
| – | – | ﹤0.01% | 1531 |
|
|
2020
Q4 | $354K | Hold |
18,926
| – | – | ﹤0.01% | 1665 |
|
|
2020
Q3 | $321K | Sell |
18,926
-3,626
| -16% | -$70.5K | ﹤0.01% | 1593 |
|
|
2020
Q2 | $525K | Hold |
22,552
| – | – | 0.01% | 1352 |
|
|
2020
Q1 | $189K | Hold |
22,552
| – | – | ﹤0.01% | 1733 |
|
|
2019
Q4 | $220K | Hold |
22,552
| – | – | ﹤0.01% | 1924 |
|
|
2019
Q3 | $214K | Hold |
22,552
| – | – | ﹤0.01% | 1905 |
|
|
2019
Q2 | $268K | Hold |
22,552
| – | – | ﹤0.01% | 1863 |
|
|
2019
Q1 | $397K | Hold |
22,552
| – | – | ﹤0.01% | 1591 |
|
|
2018
Q4 | $392K | Hold |
22,552
| – | – | ﹤0.01% | 1523 |
|
|
2018
Q3 | $336K | Hold |
22,552
| – | – | ﹤0.01% | 1786 |
|
|
2018
Q2 | $359K | Hold |
22,552
| – | – | ﹤0.01% | 1620 |
|
|
2018
Q1 | $320K | Hold |
22,552
| – | – | ﹤0.01% | 1642 |
|
|
2017
Q4 | $316K | Buy |
+22,552
| New | +$330K | ﹤0.01% | 1680 |
|
Other funds holding VIVO
MetLife Investment Management's VIVO Position: Q1 2023 in Review
MetLife Investment Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 23,227 shares — an estimated $771K sold.
MetLife Investment Management first reported a position in VIVO in Q4 2017 and held it in 21 quarters. The position peaked at $771K in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.
- MetLife Investment Management reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
- MetLife Investment Management sold 23,227 Meridian Bioscience Inc shares in Q1 2023, an estimated $771K.
- MetLife Investment Management first reported a position in Meridian Bioscience Inc in Q4 2017 and held it in 21 quarters.
- MetLife Investment Management's Meridian Bioscience Inc position peaked at $771K in Q4 2022.
- 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.
Based on MetLife Investment Management's 13F filing for Q1 2023, filed 15 May 2023.